PPARG and melanoma: A further TMA (n = 194) consisted of MM metastases from 36 patients with metastatic stage IV melanoma who had participated in a randomized phase II trial using a stroma-directed biomodulatory approach combining COX-2/ PPARγ-targeting with metronomic low-dose chemotherapy [18].